Desmoid Tumor Regression with NSAIDs
Author Information
Author(s): Tanaka Keita, Yoshikawa Reigetsu, Yanagi Hidenori, Gega Makoto, Fujiwara Yoshinori, Hashimoto-Tamaoki Tomoko, Hirota Syozo, Tsujimura Tohru, Tomita Naohiro
Primary Institution: Hyogo College of Medicine
Hypothesis
Can non-steroidal anti-inflammatory drugs (NSAIDs) effectively treat sporadic intra-abdominal desmoid tumors?
Conclusion
The case report indicates that NSAID treatment may be a viable first-line option for sporadic intra-abdominal desmoid tumors.
Supporting Evidence
- The patient showed a decrease in tumor size from 95 × 70 mm to 63 × 49 mm after two years of treatment.
- No adverse events were reported during the treatment period.
- The regression rate of the tumor was 68.5%.
Takeaway
A 73-year-old man with a rare tumor saw his tumor shrink after taking a common pain reliever for two years.
Methodology
The patient was treated with etodolac, a non-steroidal anti-inflammatory drug, and monitored via CT scans.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 73-year-old male patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website